Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips

Cortical thinning in Alzheimer’s disease

June 22, 2009

…11, 2009), identify patients at risk of developing Alzheimer’s disease (Bakkour et al. Neurology 2009;72:1048-1055), and to differentiate Alzheimer’s disease from frontotemporal dementia (Du et al. Brain 2007;130(pt 4):1159-1166; free download at http://brain.oxfordjournals.org/cgi/content/full/130/4/1159). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newslette…

Fingolimod in RRMS: results from two trials

June 22, 2009

…REPORT FROM THE 2009 AAN ANNUAL MEETING – Fingolimod (FTY720), a novel sphingosine 1-phosphate receptor modulator, appears to be effective in patients with relapsing-remitting MS, according to the results from a new phase III trial. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

Predicting depression in early Parkinson’s disease

June 9, 2009

REPORT FROM THE 2009 AAN ANNUAL MEETING – An analysis of patients in the DATATOP (Deprenyl and tocopherol antioxidative therapy of parkinsonism) trial (Shoulson I. Acta Neurol Scand Suppl 1989;126:171-175) has attempted to identify factors predictive of depression onset (Uc et al. AAN 2009; abstract S23.004). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newslet…

Bilingualism: no protective effect

May 20, 2009

…REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY – An analysis of data from the longitudinal Einstein Aging Study (EAS) has found that bilingualism does not protect against or delay the onset of dementia or amnestic mild cognitive impairment (MCI) (Saunders et al. AAN 2009; abstract S02.004). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

Phase III trial results for cladribine: the CLARITY study

May 20, 2009

REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY – Oral cladribine appears to be effective in reducing relapse rates and disability progression, according to the preliminary results from the phase III CLARITY (Cladribine tablets treating MS orally) trial (Giovannoni et al. AAN 2009; abstract LBS.001). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Co…